title: Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques.
abstract: In this retrospective longitudinal cohort study we included 52 patients with Takayasu arteritis (TA) who were on regular follow-up at the Vasculitis Unit of Universidade Federal de São Paulo between 2003 and 2009. The mean age at study was 38 years and the mean age at diagnosis was 29 years. Patients were followed for a mean 74.3 months. A relapse-remitting course was observed in 41 patients (78.8%) whereas 9 (17.3%) had a monophasic course and only 2 (3.8%) patients were chronic-active. Disease remission was achieved in 50 patients (96.2%). Angiographic type V was observed in 42.3% of TA patients at diagnosis and in 61.5% during follow-up. The most affected arteries were the abdominal aorta (63.5%) and left subclavian (60.6%). Prednisone was used by 94% of TA patients and immunosuppressive agents were prescribed for 51 (98%) patients. Methotrexate was used by 82.7%, followed by cyclophosphamide (26.9%), azathioprine (25.0%), anti-TNFα agents (5.8%) and leflunomide (5.8%). Although, forty patients (76.9%) used prednisone and methotrexate as initial treatment, 75% of them developed new vascular lesions along follow-up. Eighteen TA patients (34.6%) needed to change immunosuppressive therapy due to failure or toxicity, among them 83.3% presented new lesions. Surgical treatment was performed in 34.6% of patients and restenosis was observed in 13.5% in a median time of 11 months after surgery. In conclusion besides prednisone and methotrexate is largely used in TA, the majority of patients still develop new arterial lesions along time.
authors.affiliation: Rheumatology Division, Universidade Federal de São Paulo-UNIFESP, Rua Botucatu, 740, Third Floor, São Paulo, SP 04023-900, Brazil.
authors.forename: Daniele Souza
authors.initials: DS
authors.lastname: Freitas
authors.forename: Cintia Zumstein
authors.initials: CZ
authors.lastname: Camargo
authors.forename: Henrique Ataíde
authors.initials: HA
authors.lastname: Mariz
authors.forename: Anne Elizabeth Diniz
authors.initials: AE
authors.lastname: Arraes
authors.forename: Alexandre Wagner Silva
authors.initials: AW
authors.lastname: de Souza
mesh_terms: D000328:Adult; D001012:Aorta, Abdominal / Q000473:pathology / Q000503:physiopathology; D003251:Constriction, Pathologic; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D013348:Subclavian Artery / Q000473:pathology / Q000503:physiopathology; D013625:Takayasu Arteritis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome; D014654:Vascular Patency
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011241:Prednisone; D008727:Methotrexate